PRDX5

Chr 11

peroxiredoxin 5

Also known as: ACR1, AOEB166, B166, HEL-S-55, PLP, PMP20, PRDX6, PRXV

NCBI Gene: 25824ENSG00000126432UniProt: P30044

This gene encodes a member of the peroxiredoxin family of antioxidant enzymes, which reduce hydrogen peroxide and alkyl hydroperoxides. The encoded protein interacts with peroxisome receptor 1 and plays an antioxidant protective role in different tissues under normal conditions and during inflammatory processes. The use of alternate transcription start sites is thought to result in transcript variants that use different in-frame translational start codons to generate isoforms that are targeted to the mitochondrion (isoform L) or peroxisome/cytoplasm (isoform S). Multiple related pseudogenes have been defined for this gene. [provided by RefSeq, Nov 2017]

31
ClinVar variants
8
Pathogenic / LP
0.00
pLI score
0
Active trials
Clinical Summary— PRDX5
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
8 Pathogenic / Likely Pathogenic· 20 VUS of 31 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.28LOEUF
pLI 0.000
Z-score 0.94
OE 0.68 (0.39–1.28)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.08Z-score
OE missense 0.98 (0.84–1.14)
119 obs / 121.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.68 (0.39–1.28)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.98 (0.84–1.14)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.19
0≤1.21.6
LoF obs/exp: 7 / 10.2Missense obs/exp: 119 / 121.5Syn Z: -1.08

ClinVar Variant Classifications

31 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic2
VUS20
Likely Benign3
6
Pathogenic
2
Likely Pathogenic
20
VUS
3
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
6
0
6
Likely Pathogenic
0
0
2
0
2
VUS
0
18
2
0
20
Likely Benign
0
3
0
0
3
Benign
0
0
0
0
0
Total02110031

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PRDX5 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
PEROXIREDOXIN 5; PRDX5
MIM #606583 · *
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer.
Wang R et al.·Adv Sci (Weinh)
2024
Prdx5 regulates macrophage polarization by modulating the TLR4/NF-κB pathway to promote apoptosis in chronic prostatitis.
Wu W et al.·Int Immunopharmacol
2025
Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development.
Wang R et al.·Int J Biol Macromol
2024
Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.
Bovari-Biri J et al.·Cells
2023Functional
Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.
Wan S et al.·BMC Cancer
2025
Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.
Wang R et al.·Br J Cancer
2025Cohort
Identification of proteomic signatures associated with lung cancer and COPD.
Pastor MD et al.·J Proteomics
2013Clinical trial
The prognostic values of the peroxiredoxins family in ovarian cancer.
Li S et al.·Biosci Rep
2018
Peroxiredoxin 5 overexpression decreases oxidative stress and dopaminergic cell death mediated by paraquat.
Duarte-Jurado AP et al.·Cells Dev
2023
Serum Immune-Response Protein Biomarkers Based on Olink Technology for Diagnosis of Ischemic Stroke.
Wang H et al.·J Proteome Res
2025
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
CD133+ Lung Cancer Stem-like Cells Resist Plasma-activated Medium Through PRDX5-mediated Antioxidant Defense.
Yu NN et al.·Anticancer Res
2026
Acetylation of PRDX5 aggravates the oxidative stress and apoptosis of retinal neurons induced by ischemia-reperfusion.
Lu S et al.·Tissue Cell
2026
Effects of Selenium Nanoparticles and Sodium Selenite Supplementation on Cryopreserved Ram Sperm Quality, Oxidative Status, and PRDX5 Gene Expression.
Kaya C et al.·Animals (Basel)
2026🔓 Open Access
IER3 drives the transition from sepsis-associated AKI to CKD by suppressing the mitochondrial translocation of PRDX5.
Dou Q et al.·Cell Mol Life Sci
2025🔓 Open Access
PRDX5 Regulates Mitochondrial Function and Nuclear Spreading in Myogenesis and Acts With PRDX3 to Delay Muscle Aging.
Suh J et al.·J Cachexia Sarcopenia Muscle
2025🔓 Open Access
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools